InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

Current share price for SPL : $0.725 0.01 (1.40%)+

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$346 DEP irinotecan phase 2 commences after positive phase 1 7 May 2020 9:42AM $0.960 $0.725 fallen by 24.48%
$346 Starpharma presents at Macquarie Australia Conference 5 May 2020 9:30AM $1.000 $0.725 fallen by 27.50%
$346 SPL7013 shows significant activity against coronavirus 15 Apr 2020 7:25PM $0.930 $0.725 fallen by 22.04%
$346 Quarterly Cashflow and Activity Report 7 Apr 2020 9:46AM $0.900 $0.725 fallen by 19.44%
$346 Appendix 2A 20 Mar 2020 3:33PM $0.760 $0.725 fallen by 4.61%
$346 Okamoto licenses VivaGel antiviral condom in Asian countries 4 Mar 2020 9:44AM $1.005 $0.725 fallen by 27.86%
$346 Starpharma appoints David McIntyre and Appendix 3X 2 Mar 2020 9:23AM $1.025 $0.725 fallen by 29.27%
$346 Interim Report and Half-Year Financial Results 24 Feb 2020 9:33AM $1.220 $0.725 fallen by 40.57%
$346 VivaGel BV launched in Asia 13 Feb 2020 9:37AM $1.130 $0.725 fallen by 35.84%
$346 David McIntyre appointed as non-executive director 12 Feb 2020 9:39AM $1.125 $0.725 fallen by 35.56%
$346 Starpharma receives US$3M milestone from AstraZeneca 11 Feb 2020 9:15AM $1.160 $0.725 fallen by 37.50%
$346 Shareholder Update January 2020 30 Jan 2020 10:51AM $1.170 $0.725 fallen by 38.03%
$346 Quarterly Cashflow Report 29 Jan 2020 10:06AM $1.170 $0.725 fallen by 38.03%
$346 Appendix 3B 24 Jan 2020 12:27PM $1.195 $0.725 fallen by 39.33%
$346 Commencement of phase 1 trial for AZD0466 utilising DEP 30 Dec 2019 8:48AM $1.195 $0.725 fallen by 39.33%
$346 Starpharma receives $4.9M R&D tax incentive refund 16 Dec 2019 9:10AM $1.275 $0.725 fallen by 43.14%
$346 DEP cabazitaxel progresses to phase 2 on positive results 10 Dec 2019 9:41AM $1.225 $0.725 fallen by 40.82%
$346 Change in Director's Interest Notice - J Fairley 4 Dec 2019 4:21PM $1.310 $0.725 fallen by 44.66%
$346 Appendix 3B 4 Dec 2019 4:16PM $1.310 $0.725 fallen by 44.66%
$346 AGM Results 21 Nov 2019 5:58PM $1.320 $0.725 fallen by 45.08%
$346 AGM - Chairman address and CEO presentation 21 Nov 2019 2:56PM $1.305 $0.725 fallen by 44.44%
$346 VivaGel condom receives regulatory approval in Europe 20 Nov 2019 4:34PM $1.320 $0.725 fallen by 45.08%
$346 2019 AGM details 19 Nov 2019 8:37AM $1.290 $0.725 fallen by 43.80%
$346 UK launch of VivaGel BV 13 Nov 2019 8:36AM $1.330 $0.725 fallen by 45.49%
$346 Becoming a substantial holder - SPL 12 Nov 2019 8:17AM $1.280 $0.725 fallen by 43.36%

401 - 425 of 877 results

Page 17 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.